This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
Best & Worst Performing ETFs to Start 2019
by Sweta Killa
We have highlighted some ETFs that are off to a good start in 2019 and some that have had a rough start.
Top & Flop Zones of Q3 & Their ETFs
by Sweta Killa
Some corners of ETF investing have performed exceptionally well in the third quarter while some are lagging.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
4 Sector ETFs That Beat the Market in Q3
by Sweta Killa
We have highlighted four sector ETFs that have gained in double digits in the third quarter and could be better plays in the months ahead, should the trends prevail.
Top Performing Active ETFs & Tesla's Best-Case Scenario
by Neena Mishra
Neena Mishra talks with COO of ARK Investment Management, the firm behind most innovative ETFs that have consistently delivered excellent performance.
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
4 Sector ETFs That Beat the Market in August
by Sweta Killa
We have highlighted four sector ETFs that easily crushed the market in August and could be better plays in the months ahead should the trends prevail.
Top and Flop ETFs of August
by Sanghamitra Saha
Inside the top and worst performing ETFs of August.
Genomic Revolution ETF (ARKG) Hits New 52-Week High
by Sanghamitra Saha
This genomic revolution ETF hits a new 52-week high. Are more gains in store for this ETF?